from relocating some product from the old production line to the new one in Q1/2018; as well as a non-cash one-time expense of setting higher allowance for inventories declining value resulted from the
Microsoft Word - 2019 Results Notification letter_Eng _Final_ February 11, 2020 The Director and Manager The Stock Exchange of Thailand Re: Information concerning Fiscal Year 2019 Operating Results
) Resolved propose to the Annual Ordinary General Meeting of Shareholders to consider and approve the Balance Sheet and Profit and Loss Statement of the Company for the fiscal year ended December 31, 2017
will be made on May 24, 2019. The mentioned right will be further approved by the AGM 2019. 2. Approved to propose to the AGM to consider and approve the financial statement of the company for the fiscal
Consolidated Financial Results 1. Operating Results Revenues In the first half of fiscal year 2021, the total consolidated revenues were 10,386 million baht, decreasing of 655 million baht or 6% y-y. In the
accounts of 10,772 million baht or 12% of total accounts receivable, decreasing from 10,951 million baht or 12% of total accounts receivable at the end of previous fiscal year. For default receivables in
10,470 million baht or 11% of total accounts receivable, comparing to that of 10,951 million baht or 12% of total accounts receivable at the end of previous fiscal year. The delinquent account receivables
IP_AC/001/2563 February 24, 2020 Subject Management’ discussion and analysis for the fiscal year ended December 31, 2019 To President The Stock Exchange of Thailand Interpharma Public Company Limited
, 2020 Subject Management’ discussion and analysis for the fiscal year ended December 31, 2019 To President The Stock Exchange of Thailand Interpharma Public Company Limited ( “ the Company” ) would like